Close

Marina Biotech (MRNA) Enters Agreement to Acquire Turing Pharma's Intranasal Ketamine Program

May 3, 2016 9:07 AM EDT Send to a Friend
Marina Biotech, Inc. (OTC: MRNA) and Turing Pharmaceuticals AG a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login